e-learning
resources
ERJ
2022
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
In vitro
assessment of triple combination therapy for the most common disease-associated mutation in cystic fibrosis
Han-I Yeh, Tzyh-Chang Hwang
Source:
Eur Respir J, 59 (2) 2102380; 10.1183/13993003.02380-2021
Journal Issue:
February
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Han-I Yeh, Tzyh-Chang Hwang.
In vitro
assessment of triple combination therapy for the most common disease-associated mutation in cystic fibrosis. Eur Respir J, 59 (2) 2102380; 10.1183/13993003.02380-2021
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Cystic fibrosis and intestinal organoids
Asbestosis
Related content which might interest you:
A novel
CFTR
mutation found in a Chinese cystic fibrosis patient
Source: Eur Respir J 2005; 26: Suppl. 49, 402s
Year: 2005
Identification of a new cystic fibrosis transmembrane regulator mutation in a severely affected patient
Source: Eur Respir J 2002; 19: 374-376
Year: 2002
Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two
F508del
alleles
Source: ERJ Open Res, 5 (2) 00082-2019; 10.1183/23120541.00082-2019
Year: 2019
First identified “severe” mutations and extended rearrangements in the CFTR gene in Russian cystic fibrosis patients
Source: Virtual Congress 2020 – Cystic fibrosis
Year: 2020
Genotype specific therapies for cystic fibrosis
Source: Annual Congress 2004 - New approaches to cystic fibrosis: from cells and molecules to novel therapies
Year: 2004
Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis
Source: Eur Respir J 2011; 37: 59-69
Year: 2011
Lumacaftor-Ivacaftor combination therapy in Phe508del homozygous CF patients with end-stage lung disease – preliminary results
Source: International Congress 2017 – Cystic fibrosis: treatments and monitoring
Year: 2017
Evaluation of
MRP1-5
gene expression in cystic fibrosis patients homozygous for the ΔF508 mutation
Source: Annual Congress 2003 - Cystic fibrosis: new genes, new controversies
Year: 2003
Cystic fibrosis: prospects for therapy of some class 1 mutations
Source: Annual Congress 2007 - Cystic fibrosis: will the new biology deliver?
Year: 2007
Genotype/phenotype correlation of the G85E mutation in a large cohort of cystic fibrosis patients
Source: Eur Respir J 2004; 23: 679-684
Year: 2004
Genotype-phenotype correlation in cystic fibrosis patients bearing a novel complex allele
Source: Annual Congress 2011 - Cystic fibrosis: clinical and laboratory studies
Year: 2011
Long-term outcomes and clinical worsening in cystic fibrosis patients with at least one residual function mutation
Source: International Congress 2018 – Cystic fibrosis in adults: current research
Year: 2018
CFTR gene mutations detected in Japanese individuals with cystic fibrosis
Source: Eur Respir J 2006; 28: Suppl. 50, 716s
Year: 2006
The cystic fibrosis airway milieu enhances rescue of F508del in a pre-clinical model
Source: Eur Respir J, 52 (6) 1801133; 10.1183/13993003.01133-2018
Year: 2018
Targeting CFTR as a therapy for cystic fibrosis
Source: Lung Science Conference 2010 - Biology of gene-environment interactions in the lung
Year: 2010
Topical application of gentamicin causes a reduction of sweat ion concentration in cystic fibrosis patients carrying nonsense mutations
Source: Eur Respir J 2001; 18: Suppl. 33, 9s
Year: 2001
High morbidity and mortality in cystic fibrosis patients compound heterozygous for 3905insT and ΔF508
Source: Eur Respir J 2001; 17: 1181-1186
Year: 2001
Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: Evaluation of exacerbations and lung function
Source: International Congress 2016 – Cystic fibrosis: inflammation, microbiology, management and monitoring
Year: 2016
Combination of ENaC and CFTR mutations may predispose to cystic fibrosis-like disease
Source: Eur Respir J 2009; 34: 772
Year: 2009
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept